Navigation Links
Urologists Outraged over Government Panel's Recommendation to Stop Life-Saving Prostate Cancer Testing
Date:5/21/2012

TALLAHASSEE, Fla., May 21, 2012 /PRNewswire/ -- The Large Urology Group Practice Association (LUGPA), representing more than 1,800 urologists, today discredited recommendations by the U.S. Preventive Services Task Force (USPSTF) to stop prostate cancer testing.

USPSTF's final recommendation, released today, instructs physicians to discourage asymptomatic men from having the PSA test. This comes despite overwhelming opposition from urologists, prostate cancer patients, and patient advocacy groups, all who have confirmed the importance of these life-saving measures.

"We are appalled at the USPSTF's recommendation that healthy men should no longer receive prostate-specific antigen (PSA) blood tests as part of routine cancer screening," said Dr. Deepak A. Kapoor, President of LUGPA and Chairman and CEO of Integrated Medical Professionals, PLLC. Kapoor added, "Failing to detect cancer early will create a public health catastrophe in 5-10 years."

The largest study on screening, the European Randomized Study for the Screening of Prostate Cancer (ERSPC) published its updated findings in the March issue of the New England Journal of Medicine. This demonstrated a 21 percent survival advantage to PSA screening for all patients, and furthermore, for those with the longest follow-up (over 10 years) this increased to 38 percent.  This is consistent with experience in the United States, where death rates from prostate cancer have declined by nearly 40 percent over the last two decades, although the incidence of the disease has been relatively stable.

Dr. Kapoor states, "USPSTF clearly 'cherry-picked' data to support what can only be viewed as a pre-conceived bias against screening.  The task force did not include any physician who treats prostate cancer, and ignored credible studies and epidemiological data demonstrating a significant survival advantage to early detection…we are not detecting more cancer; we are detecting cancer earlier and saving lives."

The USPSTF's downgrade of prostate cancer screening to a "D" recommendation at this time is irresponsible and inexplicable. It even would deny screening to those at the greatest risk for prostate cancer— African-Americans and those with a family history of prostate cancer.  These patients urgently need to be educated about their risks of developing cancer, and the role that screening could play in early diagnosis and treatment.  

"The recommendation not only grossly misrepresents the current literature about screening, but makes a blanket statement about what's right for all men," said Kapoor. "Every man has a right to make his own decision about screening after discussion with his own doctor. We cannot allow an unaccountable government entity to deny patients access to tests that saves the lives of thousands of Americans every year."

LUGPA joins the American Urological Association (AUA) and the American Association of Clinical Urologists (AACU) in support of PSA screening for well-informed men who wish to pursue early diagnosis for a disease that is the second leading cause of cancer death in men.  The USPSTF's recommendations risk undoing 20 years of progress in patient education and puts the lives of tens of thousands of men at risk.  All concerned citizens are encouraged to contact government representatives to demand the government not restrict access to this life-saving testing as a result of misguided recommendations.

Please visit LUGPA's website for additional information on PSA screening.

About LUGPA

LUGPA represents 95 large urology group practices in the United States, with more than 1,800 physicians who make up more than 20 percent of the nation's practicing urologists. LUGPA and its member practices are committed to best practices, research, data collection, and benchmarking to promote quality clinical outcomes. Visit http://lugpa.org/default.aspx for more information about LUGPA.


'/>"/>
SOURCE Large Urology Group Practice Association
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Urologists Debunk Misleading, Grossly Inaccurate Prostate Cancer Biopsy Study
2. JoVE partners with US government to publish cutting-edge defense research
3. Potassium Iodide Sales Surge on Heels of Large Government Order
4. BioPower Systems Awarded $5 Million from Victorian Government
5. McGladrey Manufacturing and Distribution MonitorĀ® Shows Business Accelerating Despite Concerns About Government Gridlock
6. GeoVax Awarded $3.6 Million Grant by U.S. Government for its HIV/AIDS Vaccine Program
7. Healthcare Distribution Management Association Names Patrick Kelly New Senior Vice President, Government Affairs
8. University of Utah and Navigen Pharmaceuticals Announce a New Government Contract to Advance Slit2N for the Treatment of Hemorrhagic Fever and Anthrax Exposure
9. The Israeli Governments Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology
10. Transgenomic Awarded $1,070,453 From U.S. Government Under the Patient Protection and Affordable Care Act
11. U.S. Government Grants Awarded for Further Development of Adult Stem Cell Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- - New FDA action date of July ... date of July 22, 2016   --> ... 2016   - Lifitegrast has the potential ... the treatment of signs and symptoms of dry eye disease in ... be the only product approved in the U.S. in the past decade indicated for the ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... and triple quad LC-MS, host live demos and poster sessions, and present on ... exhibition. The conference takes place March 6 to 10 at the Georgia World ...
(Date:2/4/2016)... 2016 Beike Biotechnology, the Shenzhen ... a ceremony in late 2015 to mark their successful ... 2016. --> --> ... Personalized Cell Therapy" was hosted by the Shenzhen Cell ... subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... MENLO PARK, Calif. , Feb. 4, 2016 ... the "Company"), a biopharmaceutical company focused on the development and ... present at the 18 th Annual BIO CEO ... 10:00 a.m. EST in New York, NY ... CEO, will provide an update on the ongoing clinical trial ...
Breaking Biology Technology:
(Date:2/3/2016)... DUBLIN , Feb. 3, 2016 /PRNewswire/ ... announced the addition of the "Emotion ... NLP, Machine Learning, and Others), Software Tools ... Application Areas, End Users,and Regions - Global ... offering. --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 Technology Enhancements ... presents an analysis of the digital and computed radiography ... Malaysia , and Indonesia ... trends and market size, as well as regional market ... country and discusses market penetration and market attractiveness, both ...
(Date:2/1/2016)... -- Today, the first day of American Heart Month, the ... first of its kind workplace health solution that leverages ... first application of Watson to ... Welltok will create a new offering that combines AHA,s ... on Welltok,s health optimization platform. The effort is intended ...
Breaking Biology News(10 mins):